News

Sanofi, Regeneron fall after late-stage data for COPD therapy
Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...
Nasdaq3d
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
The primary endpoint for AERIFY-1 and AERIFY-2 was the reduction in the annualized rate of acute moderate or severe COPD exacerbations with itepekimab treatment. AERIFY-1 met the primary endpoint ...
Seeking Alpha1y
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved ...
Home page Seeking Alpha - Power to Investors Create Free Account About Premium FREE Newsletters ...
Nasdaq3d
Regeneron, Sanofi: COPD Drug Itepekimab Meets Primary Goal In 1 Phase 3 Trial, But Fails In Another
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that Itepekimab met the primary endpoint in one of two trials of chronic ...